• Welcome to the new Inserm Transfert website
    Welcome to the new Inserm Transfert website

… Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, specialised in technology transfer and life sciences, was founded in 2000.

It is the private subsidiary of Inserm under a Public Service Delegation agreement. The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological to clinical research, and are used for the creation of economic and societal value.

Are you a
researcher?

Access your portal

Read more

Are you a company?

Access your portal

Read more

News press

February 06, 2018

2èmes rencontres du parcours pré-entrepreneurial : Inserm Transfert dévoile de nouveaux dispositifs de soutien à la création d’entreprise de croissance

Paris, 6 Février 2018 – Les 1er et 2 février 2018 s’est tenue la seconde édition des Rencontres du Parcours Pré-Entrepreneurial mis en place par Inserm Transfert pour accompagner les chercheurs inventeurs et les aider à mettre en place les fondamentaux…
November 23, 2017

L’Inserm, Inserm Transfert et la SATT Toulouse Tech Transfer (TTT) signent un accord de partenariat pour le financement de projets de maturation à Toulouse

Paris, November 23th, 2017 – Le professeur Yves Lévy, Président Directeur Général de…
November 22, 2017

RaDiCo (Inserm) et Boehringer Ingelheim France annoncent un partenariat autour de la Fibrose Pulmonaire Idiopathique

Paris, November 22th, 2017 – RaDiCo, programme national de cohortes sur les maladies…
Our technology offer
Read more
Our strategic innovation domains
Read more
1673
PATENT FAMILIES*
15
MILLIONS OF EUROS INVESTED IN MATURATION
400
NUMBER OF CONTRACTS AND LICENSES*
281
PROJECTS DETECTED*
* For the year 2017
ILiAD
ILiAD
The Team run by Camille Locht, Inserm Research Director and Director of Inserm U1019, located in the Pasteur Institute in Lille, has developed an attenuated strain of Bordetella pertussis with the...
SILTISS
SILTISS
The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the George Winter Prize from the European Biomaterials Society, has developed a...
MEDIMMUNE
MEDIMMUNE
Since 2011, MedImmune, the AstraZeneca international biological substances unit, has contributed to the advancement of Inserm laboratory research in several therapeutic areas, including oncology,...
COHORTES
COHORTES
INSERM TRANSFERT has developed unique expertise in the development and negotiation of public/private partnerships (PPP) linked to research projects involving human beings (in particular, cohorts,...
prev
next
ILiAD
ILiAD
The Team run by Camille Locht, Inserm Research Director and Director of Inserm U1019, located in the Pasteur Institute in Lille, has developed an attenuated strain of Bordetella pertussis with the aim of developing a new effective vaccination vector against various pathogens,  
SILTISS
SILTISS
The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the George Winter Prize from the European Biomaterials Society, has developed a natural biocompatible hydrogel which is biodegradable
MEDIMMUNE
MEDIMMUNE
Since 2011, MedImmune, the AstraZeneca international biological substances unit, has contributed to the advancement of Inserm laboratory research in several therapeutic areas, including oncology, respiratory and inflammatory diseases and autoimmune diseases.  
COHORTES
COHORTES
INSERM TRANSFERT has developed unique expertise in the development and negotiation of public/private partnerships (PPP) linked to research projects involving human beings (in particular, cohorts, biobanks and clinical studies).
IMMUNOSCORE
IMMUNOSCORE
IMMUNOSCORE® measures the density of two T lymphocyte populations – CD8 and CD3 – which are found within and at the periphery of tumours.
prev
next